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Human cytomegalovirus (HCMV) elicits a very large burden on the immune system, with approximately one
in ten T cells being reserved solely to manage this infection. However, information on the clonotypic compo-
sition of these vast T-cell populations is limited. In this study, we sequenced 116 T-cell receptor (TcR)
/-chains specific for the highly immunogenic HLA-B*3501-resticted epitope IPSINVHHY from the pp65
antigen. Interestingly, T cells recovered from all donors bore an identical or near-identical TRBV28/TRBJ1-
4/TRAV17/TRAJ33 TcR. The ability to predict the responding  TcR repertoire before viral infection should
prove a powerful tool for basic and clinical immunology.
Human cytomegalovirus (HCMV) is a betaherpesvirus (hu-
man herpesvirus 5) that infects 30 to 70% of individuals in
developed countries and upwards of 90% of individuals in
developing countries (18, 25). After primary contact, typically
through bodily fluid transmission, HCMV quickly infects var-
ious cells of myeloid lineage and ultimately establishes a life-
long persistence in the host (24). Normally, a healthy immune
system offers lifelong suppression against both primary and
latent HCMV-associated pathologies, and large numbers of
HCMV-specific CD8 and CD4 T cells are observed in the
peripheral blood of healthy virus carriers (27). However, if the
immune system is weakened, through neonatal immaturity,
human immunodeficiency virus infection, or drug-induced im-
munosuppression, the virus can escape suppression, prolifer-
ate, and initiate pathogenesis. The immune mediators primar-
ily responsible for suppressing HCMV are thought to be
CD8 and CD4 T cells. This idea is supported by the results
of early-phase trials showing that the adoptive transfer of
HCMV-specific T cells into immunocompromised patients can
successfully prevent HCMV viremia and associated diseases
(4, 10, 19, 22, 34).
In recent times, numerous large-scale mapping projects have
been carried out to identify the precise targets of HCMV-
specific T cells and, thus far, approximately 100 CD8 and
CD4 T-cell epitopes have been mapped across 15 HCMV
proteins (reviewed in reference 4). Accordingly, data are now
being quickly amassed regarding the immunogenicity and im-
munodominance of these peptides, along with the magnitudes,
fluctuations, and phenotypes of the responding T-cell popula-
tions. Information on the clonotypic composition of these vast
T-cell populations is, however, limited. Of the 100 mapped
HCMV epitopes, only four (HLA-A*0201- and B*0702-re-
stricted epitopes) have been characterized with regard to the
responding T-cell receptor (TcR) repertoire. The present
study was aimed toward expanding this knowledge through the
detailed characterization of the TcR repertoire used by ex
vivo-isolated T cells specific for the highly immunogenic, HLA-
B*3501-binding epitope 123IPSINVHHY131 (herein referred to
as IPS) from the pp65 protein of HCMV (2, 5).
Five healthy, HCMV-seropositive, HLA-B*3501-positive in-
dividuals were enrolled in the study. Initially, peripheral blood
mononuclear cells (PBMCs) were freshly isolated from each
donor; stained with CD3 monoclonal antibody (MAb), CD8
MAb, CD19 MAb (BD Biosciences, NJ), and a multimer of the
IPS/HLA-B*3501 complex (ProImmune, Oxford, United King-
dom); and analyzed by flow cytometry. The frequency of IPS/
HLA-B*3501-specific T cells was found to range from 0.25% to
1.87% (average, 0.81%) of CD8 cells (data not shown). These
frequencies are consistent with results from a previous study
that also exploited IPS/HLA-B*3501 multimers (11) and verify
the highly immunogenic nature of the IPS peptide. In order to
dissect the total IPS-specific response into separate TcR V
gene families, we costained the PBMCs with one of 22 V-
specific MAbs (Beckman Coulter, Fullerton, CA). The results
of this analysis are shown in Fig. 1. Obvious TcR V gene
restriction was observed across all individuals, with each donor
utilizing only 1 to 6 TRBV genes from an available array of 22.
Significantly, four of the five donors exhibited clear gene skew-
ing toward the TRBV28 family. These TRBV28 expansions
ranged from 19% to 55% (average, 34%) of the total IPS-
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specific response. It is of interest that T cells from donors D4
and D3 stained with only the TRBV28 MAb, while donors D2
and D1 also responded with expansions of T cells expressing
the TRBV9 and TRBV20 genes. Overall, the IPS-specific T
cells found in unrelated, HLA-B*3501-positive individuals ex-
pressed a predictable TRBV gene profile, and this observation
represents a classic example of the immunological phenome-
non of “TcR bias” (29).
To further characterize the virus-specific T-cell response, we
studied the clonal diversity and TcR junctional rearrangements
of IPS-specific T cells directly ex vivo. Using a previously de-
scribed method (13), IPS-specific T cells were sorted directly
from PBMCs to a purity of at least 96% using the peptide-
HLA multimer. The TcR transcripts were then extracted from
the pool, cloned, and sequenced. Figure 2a shows the amino
acid sequences extrapolated from this junctional, complemen-
tarity-determining region 3 (CDR3) DNA sequence analysis.
All recovered TRBV28 chains exhibited a strict CDR3 span of
13 residues and an exclusive pairing with TRBJ1-4. A set of
residue-identical (so-called public) TRBV28 chains was recov-
ered from D4 and D2. The remaining TRBV28 chains dis-
played minor variations around these core consensus se-
quences. A proline (P) residue was favored at position 4 of the
CDR3 region, while glycine (G) at position 5 and threonine
(T) at position 6 were also frequently observed. Additionally,
substitutions at these positions nearly always involved either
synonymous residues or an atomically similar amino acid com-
prising a small and uncharged side chain.
In light of this fastidious -chain selection, we next won-
dered if the -chain that paired with the TRBV28/TRBJ1-4
chain might also be restricted. Four IPS-specific, TRBV28
T-cell clones were raised from donor D4, and a full panel of
34 TRAV PCR primers was used to identify the -chain that
paired with TRBV28/TRBJ1-4 (method described previ-
ously [13]). Direct sequencing revealed that all clones were
likely to have originated from the same progenitor and that
the TRBV28/TRBJ1-4 -chain paired with a TRAV17/
TRAJ33 -chain (Fig. 2b). Using a TRAV17 primer, we
then proceeded to amplify TRAV17 transcripts from the
sorted pool of IPS-specific cells from all five donors. The
results of the TRAV17 sequencing, shown in Fig. 2a, re-
vealed a high degree of restriction, very similar to that seen
with the TRBV28 chains. All recovered TRAV17 chains
exhibited a strict CDR3 span of 13 residues and an exclusive
pairing with TRAJ33. Moreover, two further sets of residue-
identical (public) TRAV17/TRAJ33 transcripts were recov-
ered from donors D4, D1, and D3 and from donors D2, D5,
and D1 (Fig. 2a) and, like the TRBV28 chains, the remain-
ing TRAV17 chains exhibited patterning around these con-
sensus TRAV17/TRAJ33 sequences. It is of interest that
several of the recovered TRAV17 transcripts were encoded
entirely by germ line nucleotides (Fig. 2c). Such “N-nucle-
FIG. 1. HCMV-exposed, HLA-B*3501-positive individuals deploy CD8 T cells with biased TRBV gene usage for recognition of the IPS
epitope. PBMCs from five HCMV-exposed, HLA-B*3501-positive individuals were stained with an IPS/HLA-B*3501 pentamer and one of 22
TRBV-specific MAbs. Only gated percentages of 0.02% and more were considered significant. The designation TRBV follows the TcR gene
nomenclature specified by IMGT.
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otide-deficient” TcRs are thought to be expressed chiefly by
various lineages in the innate immune system ( T cells and
NKT cells) and to be very rare among  T cells (23). Of
further interest is the stringent requirement for a negatively
charged aspartic acid (E) at position 3 of the CDR3. This
residue was frequently encoded by different N nucleotides
(Fig. 2c). These data suggest a vital structural role for this
CDR3 residue when engaging the IPS/HLA-B*3501 target.
In summary, we have verified the existence of class III TcR
gene bias (29) in the IPS-specific HCMV response, with
evidence that genetically unrelated HLA-B*3501-positive
individuals deploy IPS-specific  T cells with public or
near-identical TRBV28/TRBJ1-4/TRAV17/TRAJ33 TcR
chains.
In recent years, there have been mounting reports of the
use of public  TcRs to engage a variety of human viruses,
bacteria, and cancers (reviewed in reference 14). Among
these are four public TcR signatures from HCMV, specific
for the HLA-A*0201-binding epitopes NLVPMVATV and
VLEETSVML (6, 8, 28) and the B*0702-binding epitopes
RPHERNGFTV and TPRVTGGGAM (35). Indeed, it is
becoming increasingly apparent that public  TcRs may
represent a widespread feature not only in HCMV defense
but in T-cell immunity in general. This is an intriguing
concept when considering that (i) each adult human can
draw on a stockpile of 2.5  107 different naı¨ve TcR struc-
tures to engage a foreign antigen (1) and (ii) deployment of
a single oliogoclonal T-cell population can leave a host
vulnerable to viral escape (12, 21). Presently, no clear ex-
planation for this level of TcR bias has been suggested.
There is, however, evidence suggesting that public TcRs
have specific genetic (33), functional (3, 20, 28), and struc-
FIG. 2. TcR junctional rearrangements of IPS-specific CD8 T cells. (a) One hundred eight translated CDR3  rearrangements from ex
vivo-sorted IPS-specific T cells. (b) The CDR3  rearrangements from four in vitro-derived IPS-specific T-cell clones show a pairing of the
TRBV28/TRBJ1-4 with TRAV17/TRAJ33. (c) The nucleotide redundancy exhibited by public IPS-specific T cells. The dagger (†) denotes the
donor origin and T-cell clone number. The asterisk (*) denotes multiple, codon redundant nucleotide sequences that were found in this donor.
The greyed area designates nucleotides of germ line origin. The designations TRBV, TRAV, TRBD, TRBJ, and TRAJ follow the TcR gene
nomenclature specified by IMGT. The colored areas designate common characteristics of the amino acid side chain: purple, nonpolar aliphatic;
blue, positively charged; pink, polar uncharged; yellow, negatively charged; and green, aromatic.
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tural (9, 26, 30–32) advantages over their rivals, which may
outweigh the immunological risks associated with their
dominance.
In conclusion, we have found that five of five HLA-
B*3501-positive, HCMV-seropositive donors deployed IPS-
specific T cells bearing predictable TRBV28/TRAV17 TcRs.
The identification of these and other public  T-cell pop-
ulations is important for a variety of reasons. First, they will
aid in advancing our understanding of antigen-driven T-cell
selection (20, 28) and major histocompatibility complex re-
striction (13), since they provide a fixed variable in an often
exceedingly complex biological system. Additionally, public
TcRs are valuable models for structural studies, since they
appear to represent an evolutionary pinnacle in antigen-
driven selection. Indeed, the atomic dissection of public
TcR-peptide-major histocompatibility complex engagement
can reveal distinct features which constitute superior TcR
architecture (9, 26, 31, 32). The identification of public TcRs
is also relevant clinically. First, HCMV appears to drive a
massive but dysfunctional CD8 T-cell expansion in the
elderly, which can influence factors leading to early death
(15, 36). These large T-cell populations, which frequently
utilize public TcRs, show a loss in antigen sensitivity and
cytokine production (17), exhibit a marker for end-stage
differentiation and apoptosis resistance (16), and can often
exceed one quarter of the total CD8 T-cell pool (7). Thus,
the identification of novel public T-cell populations in
HCMV immunity may allow for the rapid detection of se-
nescent cells. In theory, these cells could then be specifically
purged from the immune compartment. Finally, due to their
high affinities and traceable alloreactivity profiles, public
TcRs should also prove to be excellent candidates for future
adoptive therapies and receptor-guided therapeutics (14).
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